UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2435) 2435
Book Chapter (43) 43
Magazine Article (7) 7
Book / eBook (1) 1
Dissertation (1) 1
Government Document (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1851) 1851
life sciences & biomedicine (1798) 1798
humans (1714) 1714
male (1223) 1223
female (1044) 1044
nicotine (892) 892
animals (875) 875
nicotinic agonists - adverse effects (745) 745
adult (676) 676
smoking cessation - methods (611) 611
nicotinic agonists - therapeutic use (592) 592
smoking (568) 568
pharmacology & pharmacy (565) 565
smoking cessation (565) 565
nicotinic agonists - administration & dosage (556) 556
nicotine - adverse effects (549) 549
middle aged (532) 532
neurosciences (521) 521
neurosciences & neurology (502) 502
varenicline (480) 480
nicotine - administration & dosage (479) 479
nicotinic agonists - pharmacology (470) 470
psychiatry (467) 467
nicotine - pharmacology (395) 395
smoking - adverse effects (383) 383
rats (346) 346
treatment outcome (329) 329
receptors, nicotinic - metabolism (299) 299
tobacco (280) 280
dose-response relationship, drug (268) 268
smoking cessation programs (259) 259
substance abuse (254) 254
benzazepines - therapeutic use (237) 237
double-blind method (237) 237
mice (236) 236
quinoxalines - therapeutic use (234) 234
nicotine - therapeutic use (228) 228
time factors (222) 222
young adult (220) 220
aged (218) 218
benzazepines - adverse effects (218) 218
quinoxalines - adverse effects (217) 217
general & internal medicine (211) 211
adolescent (210) 210
risk factors (202) 202
analysis (199) 199
smoking prevention (199) 199
abridged index medicus (197) 197
rats, sprague-dawley (191) 191
research (190) 190
medicine, general & internal (188) 188
receptors, nicotinic - drug effects (180) 180
pregnancy (175) 175
tobacco use disorder - drug therapy (172) 172
bupropion - therapeutic use (171) 171
acetylcholine receptors (168) 168
health aspects (168) 168
smoking - psychology (167) 167
nicotine replacement therapy (150) 150
smoking - drug therapy (150) 150
drug therapy (143) 143
administration, cutaneous (136) 136
care and treatment (136) 136
smoking cessation - psychology (135) 135
disease models, animal (132) 132
clinical trials (129) 129
cessation (128) 128
nicotinic antagonists - pharmacology (122) 122
pharmacotherapy (122) 122
public, environmental & occupational health (121) 121
rodents (119) 119
pharmacology/toxicology (117) 117
smoking - epidemiology (117) 117
clinical neurology (115) 115
toxicology (115) 115
substance withdrawal syndrome - psychology (113) 113
biomedicine (111) 111
neurology (110) 110
social sciences (110) 110
brain - drug effects (108) 108
psychology (106) 106
schizophrenia (105) 105
tobacco use cessation products (104) 104
nicotinic agonists - toxicity (102) 102
bupropion (98) 98
cigarettes (97) 97
acetylcholine (96) 96
mice, inbred c57bl (96) 96
nicotine - toxicity (96) 96
nicotinic receptors (96) 96
rats, wistar (96) 96
pharmacology (94) 94
receptors (93) 93
studies (93) 93
benzazepines - administration & dosage (92) 92
risk assessment (91) 91
brain (90) 90
quinoxalines - administration & dosage (90) 90
addiction (88) 88
nicotinic acetylcholine receptors (88) 88
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2440) 2440
French (19) 19
German (11) 11
Spanish (10) 10
Japanese (9) 9
Dutch (5) 5
Danish (3) 3
Hungarian (3) 3
Portuguese (3) 3
Romanian (3) 3
Swedish (3) 3
Polish (2) 2
Russian (2) 2
Chinese (1) 1
Hebrew (1) 1
Italian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 05/2016, Volume 2016, Issue 5, pp. CD006103 - CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms... 
Interventions to help smokers and other tobacco users to quit | Lungs & airways | Pharmacological interventions | Varenicline | Substance Withdrawal Syndrome | Azepines | Randomized Controlled Trials as Topic | Heterocyclic Compounds, 4 or More Rings | Alkaloids | Quinolizines | Tobacco, drugs & alcohol | By treatment type | Tobacco | Azocines | Bupropion | Benzazepines | Nicotinic Agonists | Counseling | Medications | Medicine General & Introductory Medical Sciences | Nicotine | Smoking | Smoking Cessation | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Humans | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use | Index Medicus
Journal Article
Trends in cardiovascular medicine, ISSN 1050-1738, 08/2016, Volume 26, Issue 6, pp. 515 - 523
.... Nicotine exerts pharmacologic effects that could contribute to acute cardiovascular events and accelerated atherogenesis experienced by cigarette smokers... 
Cardiovascular | Cardiovascular disease | Cigarette smoking | Electronic cigarettes | Nicotine | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Smoking - adverse effects | Nicotine - administration & dosage | Humans | Cardiovascular Diseases - pathology | Smoking Prevention | Nicotine - adverse effects | Cardiovascular System - physiopathology | Time Factors | Cardiovascular Diseases - epidemiology | Vaping - adverse effects | Cardiovascular Diseases - physiopathology | Risk Assessment | Consumer Product Safety | Risk Factors | Electronic Nicotine Delivery Systems - adverse effects | Administration, Inhalation | Cardiovascular System - drug effects | Smoking Cessation - methods | Nicotinic Agonists - adverse effects | Cardiovascular System - pathology | Nicotinic Agonists - administration & dosage | Animals | Cardiovascular Diseases - chemically induced | Nicotine - pharmacokinetics | Nicotinic Agonists - pharmacokinetics | Medical policy | Smoking cessation programs | Tobacco industry | Chewing tobacco | Antismoking movement | Combustion | Hypertension | Heart failure | Cardiac arrhythmia | Tobacco smoke | Heart attacks | Toxicity | Mortality | Pharmacology | Angina pectoris | Thrombosis | Blood | Morbidity | Smoking cessation | Toxicology | Atherosclerosis | Health risk assessment | Binding sites | Veins & arteries | Index Medicus | cardiovascular disease | nicotine | electronic cigarettes
Journal Article
The Journal of biological chemistry, ISSN 1083-351X, 10/2014, Volume 289, Issue 44, pp. 30538 - 30555
Journal Article
Journal Article